

Disclosures

Personal Commercial (1)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|------------------------------|-------------------------------------|--------------------|------------------------------------|
| <i>Self</i> | | | |
| Bristol-Myers Squibb Company | Other - Registry Steering Committee | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (7)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---------------------------|--------------------------|---|
| <i>Self</i> | | | |
| American Board of Internal Medicine | Consultant Fees/Honoraria | Modest (< \$5,000) | General Cardiology |
| American College of Cardiology | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |
| American College of Cardiology--NCDR | Salary | Significant (>= \$5,000) | Acute Coronary Syndromes Arrhythmias and Clinical EP Congenital Heart Disease and Pediatric Cardiology General Cardiology Heart Failure and Cardiomyopathies Invasive CV Angio and Interventions Stable Ischemic Heart Disease Valvular Heart Disease Vascular Medicine |
| COLORADO PREVENTION CENTER † Executive Committee for trial of app by Better Therapeutics | Consultant Fees/Honoraria | Modest (< \$5,000) | Prevention |
| Massachusetts Medical Society--Associate Editor, JournalWatch Cardiology | Other | Modest (< \$5,000) | General Cardiology Heart Failure and Cardiomyopathies |
| NHLBI | Research/Research Grants | Significant (>= \$5,000) | General Cardiology |
| UpToDate | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 5/29/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 5/29/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 5/29/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 5/29/2023

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.